Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of AbbVie's ABBV-383?
ABBV-383 is a monoclonal antibody commercialized by AbbVie, with a leading Phase II program in Relapsed Multiple Myeloma;Refractory Multiple Myeloma....
Data Insights
ABBV-383 by AbbVie for Primary Systemic Amyloidosis: Likelihood of Approval
ABBV-383 is under clinical development by AbbVie and currently in Phase II for Primary Systemic Amyloidosis. According to GlobalData, Phase...